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What is known on this topic:
• Platelet activation in response to stimulation of the Protease Activated Receptor 4
(PAR4) receptor differs by race.
• Phosphatidylcholine Transfer Protein (PCTP), a regulator of PAR4 signaling, is
differentially expressed by race.
• Genetic variants can affect transcriptional activity by altering regulatory regions of DNA.
What this paper adds:
• Identifies the variant rs2912553 as contributing to racially differential expression of
PCTP.
• Identifies differential binding of a GATA1-containing complex dependent on rs2912553
genotype.
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Summary
Platelet activation in response to stimulation of the Protease Activated Receptor 4 (PAR4)
receptor differs by race. One factor that contributes to this difference is the expression level of
Phosphatidylcholine Transfer Protein (PCTP), a regulator of platelet PAR4 function. We have
conducted an expression Quantitative Trait Locus (eQTL) analysis that identifies single nucleotide
polymorphisms (SNPs) linked to the expression level of platelet genes. This analysis revealed
26 SNPs associated with the expression level of PCTP at genome-wide significance (P < 5x108

). Using annotation from ENCODE and other public data we prioritized one of these SNPs,

rs2912553, for functional testing. The allelic frequency of rs2912553 is racially-dimorphic, in
concordance with the racially differential expression of PCTP. Reporter gene assays confirmed
that the single nucleotide change caused by rs2912553 altered the transcriptional potency of the
surrounding genomic locus. Electromobility shift assays, luciferase assays, and overexpression
studies indicated a role for the megakaryocytic transcription factor GATA1. In summary, we have
integrated multi-omic data to identify and functionalize an eQTL. This, along with the previously
described relationship between PCTP and PAR4 function, allows us to characterize a genotypephenotype relationship through the mechanism of gene expression.
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Introduction
Genome wide association studies (GWAS) seek to find associations between regions of
the genome and normal or pathological traits. There are several challenges associated with
GWAS including the requirement of large sample sizes and/or effect sizes to achieve statistical
significance. One approach to overcome this challenge is to first identify associations between
gene expression and the phenotype of interest using expression profiling analysis. This is
followed by expression quantitative trait loci (eQTL) analysis, which uncovers associations
between genetic variants and gene expression.

This indirect approach can lead to the

identification of genetic variants that affect physiology in a manner that requires smaller sample
sizes than traditional GWAS (1).
Another challenge in GWAS is deciphering the mechanism by which a genetic variant
exerts its effect on the phenotype. This is complicated by the fact that 98% of SNPs identified in
GWAS are located in non-protein coding portions of the genome.

A relationship between

genotype, gene expression, and phenotype indicates that the variant acts through a transcriptionbased mechanism. Efforts by the ENCODE project and others have begun to provide annotation
to non-coding regions of the genome, identifying DNA-binding proteins, chromatin modifications,
and other epigenetic marks located throughout the genome (2, 3). Localization of eQTLs within
these annotated regions facilitates prioritization for testing, experimental design, and variant
functionalization.
We have previously conducted a gene expression profiling study to identify platelet RNAs
that are differentially expressed by demographic variables or associated with platelet
physiological phenotypes, called the Platelet RNA And eXpression (PRAX1) study (4, 5). Using
this approach, we were able to identify the expression level of the PCTP gene, encoding
Phosphatidyl Choline Transfer Protein (PC-TP), as being positively associated with platelet
reactivity in response to Protease Activated Receptor 4 (PAR4) thrombin receptor stimulation.
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PCTP RNA was also more highly expressed among self-identified black subjects as compared to
self-identified whites, in concordance with our finding that PAR4 stimulation induced platelet
aggregation more robustly in blacks than whites. The role of PC-TP protein in regulating PAR-4
function has been confirmed both by pharmacological inhibition and by siRNA silencing (4).
By performing an eQTL analysis of the PRAX1 cohort, several single nucleotide
polymorphisms (SNPs) were identified as associated with PCTP RNA levels (6). We now report
identification of the mechanism by which a common genetic variant contributes to differential
PCTP expression. Using a combination of publically available data, reporter gene assays and
electromobility shift assays (EMSA), we have confirmed that SNP rs2912553 confers differential
transcriptional potency to the locus surrounding it. rs2912553 genotype results in differential
recruitment of a GATA-1 containing complex which regulates transcription at this locus.
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Materials and Methods
The Platelet RNA and eXpression Study 1 (PRAX1)
154 healthy individuals (80 of European and 74 of African ancestry) were recruited between 2010
and 2011.

All had platelet functional phenotyping, demographic information, genome-wide

genotyping and global mRNA profiling performed. Informed consent was obtained from all
participants with the approval of the institutional review boards of Baylor College of Medicine in
Houston, TX, and Thomas Jefferson University in Philadelphia, PA. Research was conducted in
accordance with the Declaration of Helsinki.
DNA from the buffy coats of PRAX1 subjects was hybridized to the HumanOmni5 array (Illumina
Inc., San Diego, CA) as described earlier (4) and genotyped for approximately five million
markers. Genotype data was restricted to 1927172 markers passing a cohort-specific minor allele
frequency cutoff of 5%. Gene expression of PRAX1 samples was measured using the Human
Gene 1.0 ST microarray (Affymetrix, Santa Clara, CA) as described previously (5) and can be
downloaded from the Gene Expression Omnibus, accession no, GSE49921.

Expression Quantitative Trait Analysis
eQTL analysis was performed using the R statistical software (ref). We used cohort genotype and
microarray based expression data to identify significant eQTL associations within 500kb of PCTP
transcription start and stop sites. Associations were modeled using variant allele dosage (0, 1,
and 2) as the independent and PCTP expression levels as the dependent variable in a linear
regression framework as implemented in the aov R function (7). To account for confounding
variables we included age, gender and race in the regression model. Additional details on our
eQTL mapping have previously been reported (6). To assess the association between PAR4
ARS and genotype, a multivariable linear regression model was used as implemented with the R
function lm.
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Reporter Gene Assays
Luciferase reporter plasmids were constructed as follows: 32bp, 43bp and 56bp
oligonucleotides containing sequence surrounding the rs2912553 SNP were synthesized and
annealed (sticky NheI and BglII sites were formed after annealing), and ligated into pGL4.28
luciferase vector (Promega) digested with NheI and BglII. 130bp, 209bp and 454bp fragments
containing sequence surrounding rs2912553 were generated by PCR using human genomic
DNAs from rs2912553 T or C homozygous individuals as template. NheI and HindIII sites were
incorporated into the 5’ or 3’ end of primers respectively. Insert and vector were digested with
NheI and HindIII and ligated with T4 ligase. All the plasmids were validated by DNA sequencing.
Detailed primer information is shown in Table 1.
For the assays, 2 μg of reporter plasmid was co-transfected with 0.5 μg β-gal expression
plasmid into 5x105 K562 chronic myelogenous leukemia cells with Lipofectamine 2000
(ThermoFisher, Waltham, MA) based on the manufacturer’s instructions. For some experiments
40 ng siRNA (ThermoFisher) directed against a transcription factor or scrambled control was cotransfected. 24 hours post-transfection luciferase activity was analyzed on a FLUOstar OPIMA
plate reader. β-gal activity was quantified with a β-gal assay kit (ThermoFisher). The data were
presented as Luciferase/β-gal.

Electromobility Shift Assays (EMSA)
65 bp EMSA probes were generated by PCR using the reporter vectors described above
as templates and 5’ IRDye700 labeled oligonucleotide primers (IDT DNA, Coralville, IA) that
surround rs2912553.

The primer sequences were: 5’-GTTGGCCTTTCTAAGCAT-‘3 and

5’-ATGTAGATAGGGAAGTTGGTG-3’. . The probes were then gel purified and quantified. K562
nuclear extracts were made with the Subcellular Protein Fractionation Kit for Cultured Cells
(ThermoFisher). Probes and nuclear extract were allowed to bind in binding buffer (10 mM TrisHCl, pH 7.5, 50 mM NaCl, 7.5 mM MgCl2, 1 mM EDTA, 5% glycerol (v/v), 5 mM DTT, 0.1 % NP-
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40 (v/v), 0.5 mg/ml BSA, and 500 ng/ml poly (dI-dC)) for 15 minutes on ice.

For some

experiments, 4 μg super shift antibodies for GATA1 or GATA2 (Santa Cruz Biotechnology, Dallas,
TX) were added to the binding reaction. After binding, the mixtures were resolved on 5%
nondenaturing polyacrylamide gels, and scanned using an Odyssey Infrared Scanner (Li-Cor,
Lincoln, NE). The Licor Odyssey software was used for quantification of the shifted bands.

Immunoblots
5 μg pCMV-3FLAG-GATA1 plasmid or empty vector was transfected into 293 cells in a 6 well
plate using Lipofectamine 2000 (Thermo Fisher, Waltham, MA) following on manufacturer’s
protocol. 48 hours following transfection, 20 μg whole cell extracts in RIPA buffer (Thermo Fisher)
were resolved on a 12% SDS-PAGE gel. The PVDF membrane was then probed with antibodies
directed against PC-TP, GATA1, and internal loading control, GAPDH (Santa Cruz Biotechnology
Dallas, TX). The blot was scanned and bands quantified using a LI-COR Odyssey imaging
system (Lincoln, NE).
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Results
Identification and annotation of eQTLs associated with PCTP expression.
To better understand the genetic mechanisms responsible for variation in PCTP
expression we performed an eQTL analysis to identify associations between PCTP RNA levels
and SNPs located within 500kb of the PCTP gene (6, 8). This resulted in the identification of 26
SNPs whose P-value for association with PCTP RNA levels met genome-wide significance (P <
5 x 10-8) (Table 2). This set of 23 highly significant SNPs were significantly associated with the
higher level phenotype PAR4 ARS (p-value < 0.05, multiple linear regression) with multiple and
adjusted R-squared values of 0.19 and 0.12, respectively.
To prioritize these variants for functional testing, we utilized publically available data to
determine which of these SNPs coincided with markers of regulatory regions of the genome. The
sources of data we included were: (A) ChromHMM chromatin state analysis for K562 cells, which
utilizes correlations between chromatin states and known biological activity to predict biological
activity (promoter, enhancer, transcription elongation, etc.) throughout the genome (9). Due to
their myelogenous origin, K562 cells are the most biologically relevant among the ENCODE cell
types for the study of gene expression in platelets and their precursor megakaryocytes (MKs).
K562 cells have often been used to study the role of transcription factors in MK differentiation (1012).

(B) Chromatin Immunoprecipitation-Deep Sequencing (ChIP-Seq) data from CD34

hematopoietic stem cells (HSCs), and K562 cells indicating transcription factor binding. (C) ChIPSeq data from CD34 and K562 cells indicating histone H3 monomethylated on lysine 4
(H3K4me1), a marker of enhancer regions (2, 3, 13-15) (Table 2).
We prioritized SNP rs2912553, located in the first intron of the PCTP gene, for further
analysis for the following reasons (Table 2 and Fig 1A): (1) It was among the most significant
eQTLs, by P-value (9.481 x 10-30, multiple linear regression), for PCTP; (2) ChromHMM predicted
it to be located in an enhancer region in K562 cells; (3) It was one of two candidate SNPs located
10

in a region containing a strong ChIP-Seq signal for H3K4me1 in CD34 cells; (4) It was the only
candidate SNP which overlapped a transcription factor ChIP-Seq peaks in both K562 and CD34
cells. As shown in Fig 1B, in the PRAX1 cohort, individuals homozygous for the T allele of
rs2912553 expressed the highest levels of PCTP, whereas C/C homozygotes expressed the
least. In concordance with our observation that platelets from black PRAX1 subjects contained
higher amounts of PCTP, the high-expressing T allele was more common in blacks (allele
frequency = 72%), while the low expressing C allele was more common in whites (allele frequency
= 85%) (Fig 1C), suggesting this variant may be causal for the differential expression of PCTP
observed.

rs2912553 confers differential transcriptional potency
We cloned various sized fragments surrounding both alleles of rs2912553 into a luciferase
vector containing a minimal promoter (Fig. 2A) to determine if the variant results in differential
transcription enhancing potential. After transfection into K562 cells, constructs containing 56,
130, 209, and 454 bp genomic fragments demonstrated an allele-specific difference in luciferase
activity (Fig. 2B). These differences replicate the observation in the PRAX1 subjects, with the
constructs containing the T allele generating up to 3-fold the amount of luciferase activity
compared to C allele constructs. The only difference between the two constructs is the single
nucleotide change at rs2912553. Vectors containing 32 and 43 bp sized fragments resulted in
similar luciferase activity in both alleles. Interestingly the 454 bp construct resulted in lower activity
overall, suggesting a negative-regulatory element present in the additional sequence. 20 bp away
from rs2912553 (eQTL P-value = 1.0 x 10-18) is another common SNP, rs2912552, which could
potentially contribute to the transcriptional differences observed in 56 bp and larger fragments.
To test this, we generated 4 versions of the 130bp construct, which contains a large number of
predicted GATA1, GATA2, and Ets factor binding sites not present in the 209bp fragment,
containing all potential haplotypes of rs2912552 and rs2912553. We observed that rs2912552
11

genotype had no effect on transcription driven by this locus (Figure 2C). A predicted GATA1/2
binding site present in the 56bp construct, which is absent in the 43bp fragment, prompted us to
further explore the role of GATA factors in regulating transcription from this genomic locus.

rs2912553 results in differential binding of a GATA1-containing protein complex
One hypothesis to explain the difference in transcriptional potency between the two
alleles, is that the sequences containing the T allele had higher affinity for transcription factors
(TF) and other regulatory molecules. To test this possibility, we performed electromobility shift
assays (EMSAs) to investigate the interaction between DNA probes containing genomic
sequence surrounding rs2912553 and nuclear extracts from K562 cells. 65 bp probes containing
the T allele consistently recruited the highest molecular weight complex with higher affinity than
probes containing the C allele (Fig 3A). Quantification indicated the band containing this complex
was 2-fold more intense in T alleles as compared to C , indicating increased TF binding (Fig 3B).
Due to the transcription factor binding site predictions and CD34 ChIP-Seq data indicating
their binding (Fig 1A), we tested whether antibodies to GATA1 or GATA2 could disrupt or alter
the mobility of the DNA:protein complex formed on the rs2912553 containing probes. To control
for variation in the assay, we only analyzed the highest molecular weight band formed by addition
of K562 nuclear extracts to the probes. As in Fig 3A, in the absence of a specific antibody, “T”containing probes formed this highest molecular weight complex with greater affinity as indicated
by the darker intensity (Fig. 3B, lanes 3 and 4). We found that while anti-GATA1 antibodies
disrupted formation of this complex, anti-GATA2 antibodies did not (Fig 3C). Quantification of the
shifted bands indicated that addition of the α-GATA1 antibody abrogated this difference
significantly on the T allele (P = 0.004) and trending towards significance on the C allele (P =
0.07) (Fig 3D). This indicates that the highest molecular weight complex, which is differentially
recruited to the rs2912553 locus based on genotype, contains GATA1.
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GATA1 Regulates Transcription from the rs2912553 locus.
Given the evidence that GATA1 antibodies disrupted complex formation on rs2912553
containing probes, we investigated the effect of silencing or overexpression of GATA1 on
luciferase expression from the 130bp construct, which contains predicted GATA1 binding sites.
Transfecting siRNAs directed against GATA1 resulted in a 70% reduction in GATA1 mRNA and
protein level (Suppl. Figure 1 and Fig 4A). This attenuation resulted in a 90% reduction in
luciferase activity on constructs containing the T allele and a 60% reduction in constructs
containing the C allele compared to a scrambled siRNA control (Fig 4B).

Conversely,

overexpression of GATA1 resulted in a 20 and 80 fold increase in luciferase expression on the T
and C alleles respectively (Fig 4C). To confirm the role of GATA1 in regulating PCTP protein
levels, we transfected a FLAG-GATA1 expression plasmid into 293 cells, which contain low levels
of endogenous GATA1 and homozygous for the “C” allele at rs2912553 (Fig. 4D).

Over

expression of GATA1 in these cells resulted in a 40% increase in PC-TP protein (Fig 4E). This
data supports the hypothesis that GATA1 contributes to regulation of the rs2912553 locus.
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Discussion
We have previously reported the results of a genome-wide eQTL analysis in which we
identified genetic variants that are linked to the RNA level of a gene within 500kb (6). One of the
identified platelet eQTLs was SNP rs2912553 which is associated with PCTP gene expression.
Identification of this association is supported by allele-specific expression analysis of RNA-Seq
data (6).

In this analysis we found a variant (rs2960062) located in the transcribed region of

PCTP and linked to rs2912553 (D’=0.9919). The C allele of rs2960062 is associated with the T
allele of rs2912553 and is more frequently present in RNA-seq reads of PCTP transcript in
rs2960062 heterozygotes, confirming higher transcriptional activity of the linked T-allele of
rs2912553.

In this report, we present data that supports the hypothesis that variation at

rs2912553 leads to differential recruitment of a GATA1-contaning complex which regulates PCTP
expression. This mechanism results in differential expression of PCTP by race and potentially
contributes to dissimilar platelet PAR4 function.
The Genome-Wide Repository of Associations between SNPs and Phenotypes (GRASP)
database contains the results of 2082 GWAS studies. Of the 21368 SNPs in the database having
an association with a phenotype with a genome wide significance of P < 5 x 10-8, only 1.88% of
them are categorized as causing a missense mutation in a protein coding gene (16). Therefore,
the vast majority of genetic associations with phenotypes occur in non-coding, regulatory regions
of the genome. This implies that gene expression levels are key determinants of human diversity
and physiology. Here we demonstrate a link between platelet PCTP eQTL rs2912553 and PCTP
expression level. This complements our previously identified link between PCTP levels and
platelet PAR4 function. The genotype:gene expression:phenotype chain is confirmed by the
observation that platelet PCTP eQTLs are associated with platelet PAR4 reactivity.
We have previously reported that while the Alanine/Threonine variation in position 120 of
the PAR4 receptor itself determines 48% of the variance in PAR4 reactivity, PC-TP protein levels
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accounted for 18%, making it a significant factor in determining PAR4 function (17). PC-TP is
best understood as having a role in regulating lipid and glucose metabolism in the liver, and the
mechanism by which PC-TP regulates PAR4 function is still currently unknown (18-20). PCTP
associations with genome-wide or suggestive significance have been reported in other GWAS
studies, including height in African Americans (rs1549519, P = 5.8 x 10 -9) (21), LDL cholesterol
(rs11867309, P = 6.0 x 10-9), total cholesterol (rs11867309, P = 8.3 x 10-7) (22), and collagenstimulated platelet aggregation after aspirin and clopidogrel treatment (rs7210295 P = 1 x 10-6)
(23). Of particular interest, the SNP associated with lipid levels, rs11867309 is located only 1600
bp away from and is linked to rs2912553 (D’=0.991).
We have made the following observations on the effect of the rs2912553 variant on PCTP
expression: (1) The T-allele confers greater transcriptional potency than the C allele. (2) The T
allele has a greater ability to recruit a GATA-1 containing protein complex than the C allele. (3)
Reduction or enhancement of GATA1 levels results in a corresponding change in transcriptional
activity.
A limitation of this study is a lack of the identification of the transcription factor that binds
the first intron of PCTP and is altered by the rs2912553 genotype. Analysis of the DNA sequence
predicts a number of ETS-factor binding sites which are altered by rs2912553 and attenuation of
these factors with siRNA altered the enhancer potential of this locus. However, we have been
unable to definitively confirm the importance of these factors to in vivo PCTP expression.
Better understanding of the significance behind loci identified in GWAS requires
mechanistic insight as to how regulatory regions of the genome affect biology. We have utilized
genotype, gene expression and physiological data to functionalize a racially dimorphic variant that
regulates expression of PCTP, a regulator of platelet PAR4 function. More studies are needed to
evaluate the role of this variant in contributing to racial differences in platelet function in both
healthy and pathological states.
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Legends to Figures and Tables
Figure 1: Annotation of PCTP eQTLs. (A) (Top panel) Local Manhattan plot of platelet eQTL
SNPs (diamonds) in PCTP with P < 5 x 10-8 (blue dashed line). X-axis: genomic coordinates, left
Y-axis: -log10(P-value). Color indicates R2 linkage disequilibrium value relative to rs2912553. Red
line indicates recombination rate (right Y-axis). (Bottom panel) Annotation tracks (from top to
bottom): Platelet eQTL SNPs in PCTP, colors indicate R2 LD value relative to rs2912553. PCTP
gene structure. ChromHMM chromatin state predictions from K562 cells, ChIP-Seq peaks from
CD34 cells (H3K4me1, RUNX1, GATA1). (B) Differential expression of PCTP by rs2912553
genotype. Box represent interquartile range, line represents mean, whiskers represent 1.5 x
interquartile range. N=154, P-value calculated as described in Materials and Methods. (C) Allelic
frequencies of rs2912553 among black (B) and white (W) subjects in PRAX1.
Figure 2: rs2912553 genotype confers differential transcriptional potency on the
surrounding locus. (A) Schematic representation of cloned fragments surrounding rs2912553.
(B) Luciferase activity of reporter fragments by size containing the T or C allele of rs2912553. (C)
Luciferase activity of all four potential haplotypes of rs2912552 and rs2912553. Results were
normalized to cotransfected β-gal expression and presented as +/- SD. N=3 each for each
condition. P = 3 x 10-22, 2-way ANOVA for the effect of genotype on luciferase activity.
Figure 3: Differential protein binding based on rs2912553 genotype. (A) The highest
molecular weight complex protein complex from K562 nuclear extracts (arrow) bound with more
affinity to probes containing a T allele than a C allele. Representative gel. (B) Quantification of
the highest molecular weight complex from 3 independent gels as described in (A). N=3 for each
condition P = 0.02, 2-way ANOVA for the effect of genotype on shifted band intensity. (C) Addition
of anti-GATA1 antibodies disrupted formation of the complex (arrow) whereas anti-GATA2
antibodies had no effect. Representative gel. (D) Quantification of three independent gels as
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described in (C). N=3 for each condition. P= 0.0004, 2-way ANOVA for effect of antibody on
shifted band intensity. Error bars represent +/- SD
Figure 4: Transcriptional regulation of the rs2912553 locus by GATA1. (A) Western blot of
K562 cells transfected with siRNA directed against GATA1. Blots were probed for GATA1 and
GAPDH. (B) Attenuation of GATA1 expression lead to a reduction in luciferase activity driven by
the rs2912553 locus. (C) Overexpression of GATA1 results in enhanced transcriptional activity
from the rs2912553 locus. Luciferase results were normalized to co-transfected β-gal. (D)
Western blot of 293 cells transfected with a FLAG-GATA1 expression vector or control. Blots
were probed with antibodies directed against GATA1, PC-TP, and GAPDH. (E) Quantification
three independent gels as described in (D). Error bars represent +/- SD N=3 for each condition.
P-values calculated by 2-way T-test.
Table 2: Platelet eQTL SNPs for PCTP and Annotations.
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Tables
Table 1
Primer
T-32-F
T-32-R
C-32-F
C-32-R
T-43-F
T-43-R
C-43-F
C-43-R
T-56-F
T-56-R
C-56-F
C-56-R
130-F
130-R
209-F
209-R
454-F
454-R

Sequence
5’-CTAGCTTCTAAGCATCATTTCCTTCTGTAAAGGTAGA-3’
5’-GATCTCTACCTTTACAGAAGGAAATGATGCTTAGAAG-3’
5’-CTAGCTTCTAAGCATCATTTCCTTCCGTAAAGGTAGA-3’
5’-GATCTCTACCTTTACGGAAGGAAATGATGCTTAGAAG-3’
5’-CTAGCTTCTAAGCATCATTTCCTTCTGTAAAGGTAGAGATAACACCAA-3’
5’-GATCTTGGTGTTATCTCTACCTTTACAGAAGGAAATGATGCTTAGAAG-3’
5’-CTAGCTTCTAAGCATCATTTCCTTCCGTAAAGGTAGAGATAACACCAA-3’
5’-GATCTTGGTGTTATCTCTACCTTTACGGAAGGAAATGATGCTTAGAAG-3’
5’-CTAGCTTCTAAGCATCATTTCCTTCTGTAAAGGTAGAGATAACACCAACTTCCCTATCTACA-3’
5’-GATCTGTAGATAGGGAAGTTGGTGTTATCTCTACCTTTACAGAAGGAAATGATGCTTAGAAG-3’
5’-CTAGCTTCTAAGCATCATTTCCTTCCGTAAAGGTAGAGATAACACCAA CTTCCCTATCTACA-3’
5’-GATCTGTAGATAGGGAAGTTGGTGTTATCTCTACCTTTACGGAAGGAAATGATGCTTAGAAG-3’
5’-CTAGCTAGCGTTGGCCTCTCTAAGCATCATTT-3’
5'- CCCAAGCTTGCATGGTCCACTTTCCAACG -3'
5’-CTAGCTAGCGAATAGAAGGGGCCAGTGTG-3’
5’-CCCAAGCTTGCATGGTCCACTTTCCAACG-3’
5'-CTAGCTAGCTCTGGAACAATGATTTGGGAATGAC-3'
5'- CCCAAGCTTATATCTTGATCCCAAGAAGAAACCAG -3'
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Table 2
TF ChIP Seq Peak
Overlap
#

rsID

eQTL
P-value

1

rs2912559

4.80E-30

2

rs35430620

3

K562 ChromHMM
Chromatin State

H3K4me1 ChIP Seq
Peak Value*

CD34

K562

CD34

K562

11_Weak_Txn

FALSE

FALSE

0

0

4.80E-30

11_Weak_Txn

FALSE

FALSE

0

0

rs2332513

4.80E-30

11_Weak_Txn

FALSE

FALSE

1

0

4

rs2912553

9.48E-30

7_Weak_Enhancer

TRUE

TRUE

9

1

5

rs2912547

1.63E-26

9_Txn_Transition

FALSE

FALSE

1

1

6

rs2960067

1.63E-26

10_Txn_Elongation

FALSE

FALSE

0

0

7

rs2960070

1.63E-26

11_Weak_Txn

FALSE

FALSE

1

0

8

rs4627425

8.63E-25

6_Weak_Enhancer

FALSE

TRUE

1

4

9

rs8082034

8.63E-25

13_Heterochrom/lo

FALSE

FALSE

1

0

10

rs2303506

8.63E-25

10_Txn_Elongation

FALSE

FALSE

0

0

11

rs9911793

8.63E-25

13_Heterochrom/lo

FALSE

FALSE

1

1

12

rs2960061

9.28E-24

11_Weak_Txn

FALSE

FALSE

0

0

13

rs2912550

1.01E-18

11_Weak_Txn

FALSE

FALSE

2

0

14

rs2960064

1.01E-18

10_Txn_Elongation

FALSE

FALSE

0

0

15

rs2912558

1.43E-18

10_Txn_Elongation

FALSE

FALSE

1

0

16

rs2960058

9.79E-17

10_Txn_Elongation

FALSE

FALSE

1

0

17

rs2960060

2.77E-14

10_Txn_Elongation

FALSE

FALSE

0

0

18

rs890487

3.00E-12

6_Weak_Enhancer

FALSE

FALSE

4

2

19

rs2960081

3.00E-12

2_Weak_Promoter

FALSE

FALSE

9

3

20

rs2960088

4.30E-12

7_Weak_Enhancer

FALSE

FALSE

0

0

21

rs890488

1.51E-11

1_Active_Promoter

FALSE

TRUE

5

0

22

rs2960065

1.51E-11

10_Txn_Elongation

FALSE

FALSE

1

0

23

rs2033108

5.99E-11

11_Weak_Txn

FALSE

TRUE

0

0

24

rs1160027

5.84E-10

7_Weak_Enhancer

FALSE

TRUE

0

2

25

rs12051898

7.53E-10

13_Heterochrom/lo

FALSE

FALSE

0

0

26

rs2290433

7.53E-10

11_Weak_Txn

FALSE

FALSE

1

0

* Data derived from BloodChIP database(24).
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